Dan T Vogl

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. pmc Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma
    Dan T Vogl
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Biol Blood Marrow Transplant 17:1765-74. 2011
  2. ncbi request reprint Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support
    Dan T Vogl
    Bone Marrow and Stem Cell Transplant Program, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Am J Hematol 82:1071-5. 2007
  3. doi request reprint Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma
    Dan T Vogl
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
    Br J Haematol 147:531-4. 2009
  4. doi request reprint A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia
    Alexander E Perl
    Hematologic Malignancies Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 15:6732-9. 2009
  5. pmc Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis
    Rebecca L Olin
    Hematologic Malignancies Program, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Am J Hematol 83:747-9. 2008
  6. ncbi request reprint Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen cases
    Himisha Patel
    Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Leuk Lymphoma 48:885-91. 2007
  7. ncbi request reprint Medical management update: multiple myeloma
    Eric T Stoopler
    Department of Oral Medicine, University of Pennsylvania School of Dental Medicine, Philadelphia, PA 19104, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103:599-609. 2007
  8. doi request reprint Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene
    Courtney D DiNardo
    Department of Internal Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Med Oncol 25:299-302. 2008
  9. pmc Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial
    Edward A Stadtmauer
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
    Blood 117:63-71. 2011
  10. doi request reprint A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia
    Donald E Tsai
    Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 14:5619-25. 2008

Detail Information

Publications15

  1. pmc Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma
    Dan T Vogl
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Biol Blood Marrow Transplant 17:1765-74. 2011
    ..Further research is necessary to optimize dosing of both chemotherapy and radiation in obese patients...
  2. ncbi request reprint Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support
    Dan T Vogl
    Bone Marrow and Stem Cell Transplant Program, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Am J Hematol 82:1071-5. 2007
    ..Future trials comparing induction therapies should examine progression-free and overall survival after transplant to confirm this benefit...
  3. doi request reprint Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma
    Dan T Vogl
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
    Br J Haematol 147:531-4. 2009
    ..These results confirm the superiority of bortezomib over dexamethasone, regardless of prior exposure to specific therapies (clinicaltrials.gov: NCT00048230)...
  4. doi request reprint A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia
    Alexander E Perl
    Hematologic Malignancies Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 15:6732-9. 2009
    ..We sought to determine the safety and describe the toxicity of this approach by adding the mTOR inhibitor, sirolimus (rapamycin), to intensive AML induction chemotherapy...
  5. pmc Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis
    Rebecca L Olin
    Hematologic Malignancies Program, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Am J Hematol 83:747-9. 2008
    ..Here we present a case of an adult patient with steroid-dependent HLH who was treated successfully with daclizumab, a monoclonal anti-CD25 antibody, allowing successful withdrawal of steroid therapy without an increase in symptoms...
  6. ncbi request reprint Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen cases
    Himisha Patel
    Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Leuk Lymphoma 48:885-91. 2007
    ..Although detection and treatment of PTLD in liver transplant recipients remains problematic and upfront mortality is still high, long-term survival is possible. Further studies are necessary to better define treatment strategies...
  7. ncbi request reprint Medical management update: multiple myeloma
    Eric T Stoopler
    Department of Oral Medicine, University of Pennsylvania School of Dental Medicine, Philadelphia, PA 19104, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103:599-609. 2007
    ..This medical management update will review recent clinical and therapeutic advances in the field of MM and highlight issues that are important to the oral health care provider...
  8. doi request reprint Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene
    Courtney D DiNardo
    Department of Internal Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Med Oncol 25:299-302. 2008
    ..This case emphasizes the importance of monitoring for differentiation syndrome among patients receiving retinoid therapies and demonstrates the ability of bexarotene to stimulate differentiation of leukemic blasts...
  9. pmc Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial
    Edward A Stadtmauer
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
    Blood 117:63-71. 2011
    ..The provision of a primed autologous T-cell product significantly improved subsequent influenza vaccine responses. This trial was registered at www.clinicaltrials.gov as #NCT00499577...
  10. doi request reprint A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia
    Donald E Tsai
    Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 14:5619-25. 2008
    ..We therefore conducted a phase I dose escalation study to assess the maximum tolerated dose, toxicities, and activity of bexarotene in patients with non-M3 acute myeloid leukemia (AML)...
  11. ncbi request reprint Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation
    Dan T Vogl
    Abramson Cancer Center, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, 19104, USA
    Leuk Lymphoma 46:1313-20. 2005
    ..Physicians should be aware of the potential for developing a gemcitabine-induced radiation recall reaction resulting in hemodynamically significant pericardial effusion...
  12. doi request reprint The presence of amyloid in abdominal and oral mucosal tissues in patients initially diagnosed with multiple myeloma: a pilot study
    Eric T Stoopler
    Department of Oral Medicine, University of Pennsylvania School of Dental Medicine, Philadelphia, PA 19104, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod 111:326-32. 2011
    ....
  13. doi request reprint The evolving role of plerixafor in hematopoietic progenitor cell mobilization
    Yvette C Tanhehco
    Department of Pathology and Cell Biology, Columbia University, New York, New York Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
    Transfusion 53:2314-26. 2013
    ..The role of prophylactic collections and future areas of research are also presented. ..
  14. ncbi request reprint Hypertriglyceridemia presenting as "pink blood" and elevated hemoglobin level
    Donald E Tsai
    Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    Am J Hematol 83:253. 2008
  15. ncbi request reprint Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene
    Donald E Tsai
    Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA
    Am J Transplant 5:2070-3. 2005
    ..The patient was successfully treated with bexarotene, a novel synthetic retinoid analog, achieving a complete clinical response. Bexarotene may be a promising treatment for T-cell PTLD...